Unspecified Thyroid Medication

Unspecified Thyroid Medication Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 80 adverse event reports referencing Unspecified Thyroid Medication, including 15 reports in which the animal died — a 1880.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Unspecified Thyroid Medication. Reported administration routes include Oral, Unknown, Topical, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Unspecified Thyroid Medication reports are Dog (58 reports), Cat (21 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (13), Domestic Shorthair (12), Chihuahua (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Unspecified Thyroid Medication are Vomiting (19), Not eating (12), Lethargy (see also Central nervous system depression in Neurological) (12), Diarrhoea (11). Of the 80 reports with a coded outcome, Outcome Unknown is the leading category at 32.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Unspecified Thyroid Medication.